Norbert VEY
MD
-
Director of Clinical Research at 'Institut Paoli Calmettes" | Coordinator of the Clinical and Translational Program for Leukemia and Myeloid Hemopathies at t"Institut Paoli Calmettes" | Coordinator of the Labelled Center for Early Phase Trials (CLIP²), Professor of Hematology at Aix-Marseille University
AMU, IPC
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams’ dynamism and local potential.
Have a look on our testimonies
HalioDx is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
Vincent FERT
HALIODX
The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.
Julien CARVELLI
AP-HM
Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options.
Pascale TOMASINI
AP-HM, AMU
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Delphine BADINAND
APHM
your commitment to MI